Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
computational biology
lung neoplasms
macrophages
tumor escape
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
accepted:
27
04
2022
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
21
5
2022
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the mechanisms of cancer immune evasion and resistance to immunotherapy. Here, we exploited malignant pleural effusions (MPEs) from lung adenocarcinoma (LUAD) patients as a model system to decipher TIME in metastatic NSCLC. Mononuclear cells from MPEs (PEMC) and peripheral blood (PBMC), cell free pleural fluid and/or plasma were collected from a total of 24 LUAD patients and 12 healthy donors. Bulk-RNA sequencing was performed on total RNA extracted from PEMC and matched PBMC. The DEseq2 Bioconductor package was used to perform differential expression analysis and CIBERSORTx for the regression-based immune deconvolution of bulk gene expression data. Cytokinome analysis of cell-free pleural fluid and plasma samples was performed using a 48-Plex Assay panel. THP-1 monocytic cells were used to assess macrophage polarization. Survival analyses on NSCLC patients were performed using KM Plotter (LUAD, N=672; lung squamous cell carcinoma, N=271). Transcriptomic analysis of immune cells and cytokinome analysis of soluble factors in the pleural fluid depicted MPEs as a metastatic niche in which all the components required for an effective antitumor response are present, but conscripted in a wound-healing, proinflammatory and tumor-supportive mode. The bioinformatic deconvolution analysis revealed an immune landscape dominated by myeloid subsets with the prevalence of monocytes, protumoral macrophages and activated mast cells. Focusing on macrophages we identified an MPEs-distinctive signature associated with worse clinical outcome in LUAD patients. Our study reports for the first time a wide characterization of MPEs LUAD microenvironment, highlighting the importance of specific components of the myeloid compartment and opens new perspectives for the rational design of new therapies for metastatic NSCLC.
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the mechanisms of cancer immune evasion and resistance to immunotherapy. Here, we exploited malignant pleural effusions (MPEs) from lung adenocarcinoma (LUAD) patients as a model system to decipher TIME in metastatic NSCLC.
METHODS
Mononuclear cells from MPEs (PEMC) and peripheral blood (PBMC), cell free pleural fluid and/or plasma were collected from a total of 24 LUAD patients and 12 healthy donors. Bulk-RNA sequencing was performed on total RNA extracted from PEMC and matched PBMC. The DEseq2 Bioconductor package was used to perform differential expression analysis and CIBERSORTx for the regression-based immune deconvolution of bulk gene expression data. Cytokinome analysis of cell-free pleural fluid and plasma samples was performed using a 48-Plex Assay panel. THP-1 monocytic cells were used to assess macrophage polarization. Survival analyses on NSCLC patients were performed using KM Plotter (LUAD, N=672; lung squamous cell carcinoma, N=271).
RESULTS
Transcriptomic analysis of immune cells and cytokinome analysis of soluble factors in the pleural fluid depicted MPEs as a metastatic niche in which all the components required for an effective antitumor response are present, but conscripted in a wound-healing, proinflammatory and tumor-supportive mode. The bioinformatic deconvolution analysis revealed an immune landscape dominated by myeloid subsets with the prevalence of monocytes, protumoral macrophages and activated mast cells. Focusing on macrophages we identified an MPEs-distinctive signature associated with worse clinical outcome in LUAD patients.
CONCLUSIONS
Our study reports for the first time a wide characterization of MPEs LUAD microenvironment, highlighting the importance of specific components of the myeloid compartment and opens new perspectives for the rational design of new therapies for metastatic NSCLC.
Identifiants
pubmed: 35584864
pii: jitc-2021-004239
doi: 10.1136/jitc-2021-004239
pmc: PMC9119185
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All the authors with the exception of LA have nothing to disclose. LA is an employee of Takis srl.
Références
J Clin Invest. 2020 Oct 1;130(10):5380-5396
pubmed: 32663198
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32269145
Cancer Cell. 2021 Jul 12;39(7):973-988.e9
pubmed: 34115989
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Oncogene. 2017 Aug 10;36(32):4573-4584
pubmed: 28368399
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
J Immunother Cancer. 2019 Apr 18;7(1):110
pubmed: 30999958
J Thorac Oncol. 2016 Oct;11(10):1765-73
pubmed: 27418105
Cancer Res. 2010 Jan 1;70(1):338-46
pubmed: 20028869
Am Soc Clin Oncol Educ Book. 2019 Jan;39:165-174
pubmed: 31099649
Sci Rep. 2019 Feb 28;9(1):2996
pubmed: 30816121
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Signal Transduct Target Ther. 2021 Mar 26;6(1):127
pubmed: 33767177
Oncotarget. 2016 Jun 7;7(23):34217-28
pubmed: 27144518
J Cell Physiol. 2020 Mar;235(3):1877-1887
pubmed: 31397494
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Immunity. 2003 Jul;19(1):71-82
pubmed: 12871640
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Nat Commun. 2021 May 5;12(1):2540
pubmed: 33953163
Trends Immunol. 2003 Jan;24(1):25-9
pubmed: 12495721
Cancer Manag Res. 2017 Jun 23;9:229-241
pubmed: 28694705
PLoS One. 2008 Aug 27;3(8):e3077
pubmed: 18728788
Int J Cancer. 2016 Nov 15;139(10):2261-9
pubmed: 27459735
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Cancer Immunol Res. 2013 Nov;1(5):269-79
pubmed: 24777963
Cancer Cell. 2022 Mar 14;40(3):289-300.e4
pubmed: 35216676
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
J Clin Med. 2019 Nov 09;8(11):
pubmed: 31717588
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Nat Immunol. 2020 Jul;21(7):700-703
pubmed: 32577013
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Eur Respir Rev. 2016 Jun;25(140):189-98
pubmed: 27246596
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Am J Cancer Res. 2020 Sep 01;10(9):2878-2894
pubmed: 33042623
Blood. 2008 Aug 15;112(4):1269-79
pubmed: 18524989
Oncology. 2006;70(2):115-25
pubmed: 16645324
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
PLoS One. 2011;6(7):e21320
pubmed: 21789168
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Nature. 2021 Jul;595(7868):578-584
pubmed: 34135508
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823